These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 12641859)

  • 1. Indirect costs of respiratory syncytial virus hospitalizations: a commentary.
    Marks AS
    Value Health; 2003; 6(2):98-9. PubMed ID: 12641859
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis.
    Robinson JL
    Curr Med Res Opin; 2009 Jul; 25(7):1631-2; author reply 1632-3. PubMed ID: 19480611
    [No Abstract]   [Full Text] [Related]  

  • 3. Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine.
    Régnier SA
    Vaccine; 2013 Sep; 31(40):4347-54. PubMed ID: 23896421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mathematical modelling of respiratory syncytial virus (RSV): vaccination strategies and budget applications.
    Acedo L; Díez-Domingo J; Moraño JA; Villanueva RJ
    Epidemiol Infect; 2010 Jun; 138(6):853-60. PubMed ID: 20003640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of health economics to guide drug development decisions: Determining optimal values for an RSV-vaccine in a model-based scenario-analytic approach.
    Bos JM; Rietveld E; Moll HA; Steyerberg EW; Luytjes W; Wilschut JC; de Groot R; Postma MJ
    Vaccine; 2007 Sep; 25(39-40):6922-9. PubMed ID: 17707959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RSV vaccine use--the missing data.
    Drysdale SB; Sande CJ; Green CA; Pollard AJ
    Expert Rev Vaccines; 2016; 15(2):149-52. PubMed ID: 26636902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany.
    Roeckl-Wiedmann I; Liese JG; Grill E; Fischer B; Carr D; Belohradsky BH
    Eur J Pediatr; 2003 Apr; 162(4):237-44. PubMed ID: 12647196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A reply: the benefit is marginal--money can be used better].
    Lindroth M
    Lakartidningen; 2000 Mar; 97(11):1302-3. PubMed ID: 10771553
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of immunoprophylaxis in the reduction of disease attributable to respiratory syncytial virus.
    Meissner HC; Bocchini JA; Brady MT; Hall CB; Kimberlin DW; Pickering LK
    Pediatrics; 2009 Dec; 124(6):1676-9. PubMed ID: 19948632
    [No Abstract]   [Full Text] [Related]  

  • 10. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings.
    Marchetti A; Lau H; Magar R; Wang L; Devercelli G
    Clin Ther; 1999 Apr; 21(4):752-66. PubMed ID: 10363740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
    Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
    Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RSV disease--is there a role for prevention?
    Lenney W
    Respir Med; 2001 Mar; 95(3):170-2. PubMed ID: 11266232
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in The Netherlands.
    Meijboom MJ; Rozenbaum MH; Benedictus A; Luytjes W; Kneyber MC; Wilschut JC; Hak E; Postma MJ
    Vaccine; 2012 Jun; 30(31):4691-700. PubMed ID: 22561315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
    Wegner S; Vann JJ; Liu G; Byrns P; Cypra C; Campbell W; Stiles A
    Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of palivizumab for RSV prevention in high-risk children in the Netherlands.
    Nuijten M; Lebmeier M; Wittenberg W
    J Med Econ; 2009; 12(4):291-300. PubMed ID: 19811111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Is it smart to give immunoglobulin prophylaxis against respiratory syncytial virus infection?].
    Greisen G
    Ugeskr Laeger; 2001 Nov; 163(47):6607. PubMed ID: 11760548
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.
    Paes B; Steele S; Janes M; Pinelli J
    Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of local guidelines for prevention of respiratory syncytial viral infections.
    Hall CB; Stevens TP; Swantz RJ; Sinkin RA; McBride JT
    Pediatr Infect Dis J; 1999 Oct; 18(10):850-3. PubMed ID: 10530578
    [No Abstract]   [Full Text] [Related]  

  • 19. RSV vaccine in development: assessing the potential cost-effectiveness in the Dutch elderly population.
    Meijboom MJ; Pouwels KB; Luytjes W; Postma MJ; Hak E
    Vaccine; 2013 Dec; 31(52):6254-60. PubMed ID: 24148573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Total healthcare costs in the US for preterm infants with respiratory syncytial virus lower respiratory infection in the first year of life requiring medical attention.
    Stewart DL; Romero JR; Buysman EK; Fernandes AW; Mahadevia PJ
    Curr Med Res Opin; 2009 Nov; 25(11):2795-804. PubMed ID: 19788406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.